Background: Excess intramyocellular lipid induces lipotoxicity, which has been implicated in the development of insulin resistance and metabolic diseases. Although dietary capsaicin has been shown to reduce intramyocellular lipid content in mice, the underlying mechanisms remain unclear. This study aims to investigate the effects of capsaicin on lipophagy and fatty acid metabolism in skeletal muscle cells and explore the underlying mechanisms. Methods: Wild-type and transient receptor potential vanilloid channel 1(TRPV1) knock-out (KO) mice were fed a high-fat diet (HD) with or without capsaicin for 4 months. They underwent a fasting exercise to induce autophagy before measurement. C2C12 myotubes were cultured with palmitate and treated with or without capsaicin, specific antagonists, or transcription factor EB (TFEB) RNAi. Respiratory exchange ratio (RER), metabolic parameters and muscle mitochondrial fatty acid oxidation were assessed. Autophagic flux was detected using the Premo Autophagy Tandem Sensor. TFEB transcriptional activity was detected by luciferase assays. RNA-sequencing, Western blotting, and immunofluorescence were conducted to analyze the expression of lipophagy-related genes. Results: Lipid overload inhibited fatty acid oxidation and impaired autophagy flux in muscles of HD-fed wild-type mice and myotubes cultured with palmitate. Although capsaicin significantly attenuated this inhibition (p < 0.05), the effect was not replicated in the TRPV1 KO mice (p > 0.05). In cultured myotubes, capsaicin dose-dependently promoted the expression of TFEB and also enhanced TFEB transcriptional activity (p < 0.05). This led to increased acidic lysosomes, degradation of p62 and perilipin 2, and improved fatty acid oxidation (p < 0.05). The TRPV1 antagonist, the calcineurin inhibitor, or TFEB siRNA significantly inhibited the effects of capsaicin (p < 0.05). Conclusions: Capsaicin ameliorates impaired lipophagy and fatty acid oxidation in lipid-overloaded skeletal muscle cells through a TRPV1/TFEB-dependent pathway.
Background: Individuals with chronic hepatitis B virus (HBV) infection present with gut dysbiosis. Evidence suggests that gut microbiota can affect the efficacy of anti-HBV therapy. However, limited research has comprehensively explored how gut microbiota and its related metabolites interact with HBV treatment response after antiviral treatment. Our study aims to identify an association between the dominant microbial cluster and HBV treatment response during anti-viral therapies. Methods: HBV carrier mice were utilized to assess the antiviral efficacy and peripheral and intrahepatic immune responses of entecavir (ETV) and ETV plus interferon-α (EI) therapies. We analyzed the gut microbiome, metabolome, and non-parenchymal hepatic cells transcriptome to determine the role of gut microbes and related metabolites in virological and intrahepatic immune responses to ETV and EI. Mice receiving no therapy (HBV control), ETV monotherapy, and EI therapy were used for comparison. Furthermore, we used immune cells to evaluate the effects of metabolites produced by the identified bacteria. Results: EI therapy showed a greater trend toward reducing serum HBsAg and HBeAg levels compared with ETV monotherapy, and significantly decreased intrahepatic HBcAg expression. Principal coordinates analysis revealed that gut microbes and metabolites were significantly different in the EI treatment group and the ETV and HBV groups. Notably, the relative abundance of short-chain fatty acid-producing bacteria was higher in the EI group, particularly in gut Roseburia abundance and butyrate levels. Butyrate levels were also elevated in the liver. However, whether this reflects intestinal absorption or hepatic synthesis remains undetermined. Butyrate is a potent inhibitor of histone deacetylases (HDACs), which can reduce the expression of hepatic HDAC and also suppress its activity. Hepatic HDAC1 protein levels were lower in the EI group than ETV group, consistent with the possibility that butyrate may modulate HDAC1 expression. Furthermore, EI treatment increased hepatic NKG2D+ NK cells and upregulated the NK cell-mediated cytotoxicity pathway. In vitro studies revealed that 0.5 mM butyrate enhanced the cytokine response of CD8+ T cells to HBV surface-specific antigens. Conclusions: Our multi-omics analysis reveals an association of gut Roseburia abundance and butyrate levels with improved virological responses to EI therapy. In vitro, butyrate enhanced the cytokine response of HBV-specific CD8+ T cells, suggesting a hypothesis that butyrate (but does not verify mediation of the virological responses to EI) may contribute to the antiviral response. While our multi-omics and in vitro data support a testable working hypothesis that butyrate may contribute to intrahepatic immune modulation, we acknowledge that causality is not established by this study. These results provide potential possibilities for future functional investigations of butyrate-producing microbiota as an adjunct to anti-HBV therapy.
The imbalance between osteoblasts and osteoclasts is central to osteoporosis.Insulin like growth factor (IGF) has protective effects on bone. As an IGF-binding protein, the role of IGFBP in bone has also begun to come into the public's view. IGFBP not only serves as an IGF reservoir but also acts independently, interacting with other ligands to regulate cell proliferation and differentiation. Due to the complexity of the molecular network of IGF-IGFBP, the specific mechanism by which IGF-IGFBP affects bone is still unknown. This review introduces the IGF-IGFBP network and its roles in osteogenesis and osteoclast differentiation, and explores its potential as a novel therapeutic target for osteoporosis. Relevant studies were identified in PubMed and Web of Science using the keywords 'IGFBP', 'Bone', and 'Osteoporosis', followed by a comprehensive review of the literature. IGF-IGFBP regulates bone metabolism by modulating the differentiation of bone marrow mesenchymal stem cells (BMSCs) into osteogenic and adipogenic lineages, as well as the differentiation process of osteoclasts. Current studies mainly focuson osteogenic differentiation, while research on adipogenic and osteoclastogenic differentiationis limited. Some IGFBP molecules show inhibitory effects in osteogenesis, but their detailed molecular mechanisms are not fully elucidated. The IGF-IGFBP family influences bone metabolism through multiple biological pathways. However, the precise molecular mechanisms by which this system regulates bone metabolism remain incompletely understood. Future studies are needed to systematically elucidate its functional networks and pathophysiological significance in bone metabolism.
The gut microbiota plays a critical role in regulating liver metabolism and immunity, significantly influencing hepatic inflammation and fibrogenesis. However, the mechanisms by which it modulates the progression of liver fibrosis remain unclear. This study investigated the interplay between the gut microbiota and bile acids in murine liver fibrosis. A mouse model of liver fibrosis was established via intraperitoneal injection of carbon tetrachloride. The gut microbiota was depleted using an antibiotic cocktail, as confirmed through 16S rRNA sequencing. Bile acid profiles were measured using ultra-performance liquid chromatography–tandem mass spectrometry. The effects of secondary bile acids on macrophage polarization were assessed in vivo and in vitro. Gut commensal microbiota depletion exacerbated liver inflammation and fibrosis. Concomitantly, this depletion significantly reduced microbiota-derived secondary bile acids. Notably, supplementation with deoxycholic acid markedly attenuated liver fibrosis. This protective effect was associated with the inhibition of pro-inflammatory M1 macrophage polarization. Takeda G protein-coupled receptor 5 (TGR5) activation was identified as the mechanism underlying the effect of deoxycholic acid on macrophages, as a TGR5 antagonist reversed this inhibition. Mechanistically, TGR5 activation suppressed the NF-κB pathway in macrophages via the cAMP–PKA signaling cascade, thereby inhibiting hepatic stellate cell activation. Our results demonstrate that the gut microbiota–secondary bile acid–TGR5 signaling axis plays a critical role in liver fibrosis and represents a promising therapeutic target.